Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

Jay S. Markowitz, Paul Martin, Andrew J. Conrad, James F. Markmann, Philip Seu, Hasan Yersiz, John A. Goss, Peter Schmidt, Anita Pakrasi, Lucy Artinian, Natalie G B Murray, David K. Imagawa, Curtis Holt, Leonard I. Goldstein, Risë Stribling, Ronald W. Busuttil

Research output: Contribution to journalArticle

458 Citations (Scopus)

Abstract

Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA and improving histology in patients with hepatitis B infection; its role in prophylaxis against hepatitis B recurrence following liver transplantation is under investigation. Viral breakthrough and resistance, however, are a significant problem with monotherapy with either HBIG or lamivudine. The efficacy of combination lamivudine/JHBIG prophylaxis has not been reported. Fourteen patients underwent transplantation for decompensated liver disease owing to hepatitis B. Lamivudine (50 mg po/d) was begun before transplantation in 0 patients, including 4 who were HBV DNA-positive. In addition, 1 patient was HBV DNA-positive when transplanted. HBIG was given perioperatively and continued thereafter; treatment with lamivudine was maintained or initiated at the time of transplantation and continued indefinitely. The median follow-up was 387 days. Actuarial 1-year patient and graft survival was 93% (patient died of unrelated causes). At a median interval of 28 days following lamivudine treatment, all 5 HBV DNA-positive patients cleared HBV DNA from the serum; went on to clear hepatitis B surface antigen (HBsAg), before transplantation, at day 148 of lamivudine treatment. By the highly sensitive polymerase chain reaction (PCR), at a median of 346 days (range, 130-525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA. Lamivudine suppresses HBV replication in patients awaiting liver transplantation. At a median follow- up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.

Original languageEnglish
Pages (from-to)585-589
Number of pages5
JournalHepatology
Volume28
Issue number2
DOIs
StatePublished - Aug 17 1998
Externally publishedYes

Fingerprint

Lamivudine
Hepatitis B
Liver Transplantation
Immunoglobulins
Hepatitis B virus
Recurrence
Transplantation
DNA
Liver Diseases
Passive Immunization
Graft Survival
Therapeutics
Hepatitis B Surface Antigens
Virus Replication
Serum
Antiviral Agents
Histology
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology

Cite this

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. / Markowitz, Jay S.; Martin, Paul; Conrad, Andrew J.; Markmann, James F.; Seu, Philip; Yersiz, Hasan; Goss, John A.; Schmidt, Peter; Pakrasi, Anita; Artinian, Lucy; Murray, Natalie G B; Imagawa, David K.; Holt, Curtis; Goldstein, Leonard I.; Stribling, Risë; Busuttil, Ronald W.

In: Hepatology, Vol. 28, No. 2, 17.08.1998, p. 585-589.

Research output: Contribution to journalArticle

Markowitz, JS, Martin, P, Conrad, AJ, Markmann, JF, Seu, P, Yersiz, H, Goss, JA, Schmidt, P, Pakrasi, A, Artinian, L, Murray, NGB, Imagawa, DK, Holt, C, Goldstein, LI, Stribling, R & Busuttil, RW 1998, 'Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin', Hepatology, vol. 28, no. 2, pp. 585-589. https://doi.org/10.1002/hep.510280241
Markowitz, Jay S. ; Martin, Paul ; Conrad, Andrew J. ; Markmann, James F. ; Seu, Philip ; Yersiz, Hasan ; Goss, John A. ; Schmidt, Peter ; Pakrasi, Anita ; Artinian, Lucy ; Murray, Natalie G B ; Imagawa, David K. ; Holt, Curtis ; Goldstein, Leonard I. ; Stribling, Risë ; Busuttil, Ronald W. / Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. In: Hepatology. 1998 ; Vol. 28, No. 2. pp. 585-589.
@article{677a3b2f0aae4e69bc7789c2ba52ce9a,
title = "Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin",
abstract = "Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA and improving histology in patients with hepatitis B infection; its role in prophylaxis against hepatitis B recurrence following liver transplantation is under investigation. Viral breakthrough and resistance, however, are a significant problem with monotherapy with either HBIG or lamivudine. The efficacy of combination lamivudine/JHBIG prophylaxis has not been reported. Fourteen patients underwent transplantation for decompensated liver disease owing to hepatitis B. Lamivudine (50 mg po/d) was begun before transplantation in 0 patients, including 4 who were HBV DNA-positive. In addition, 1 patient was HBV DNA-positive when transplanted. HBIG was given perioperatively and continued thereafter; treatment with lamivudine was maintained or initiated at the time of transplantation and continued indefinitely. The median follow-up was 387 days. Actuarial 1-year patient and graft survival was 93{\%} (patient died of unrelated causes). At a median interval of 28 days following lamivudine treatment, all 5 HBV DNA-positive patients cleared HBV DNA from the serum; went on to clear hepatitis B surface antigen (HBsAg), before transplantation, at day 148 of lamivudine treatment. By the highly sensitive polymerase chain reaction (PCR), at a median of 346 days (range, 130-525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA. Lamivudine suppresses HBV replication in patients awaiting liver transplantation. At a median follow- up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.",
author = "Markowitz, {Jay S.} and Paul Martin and Conrad, {Andrew J.} and Markmann, {James F.} and Philip Seu and Hasan Yersiz and Goss, {John A.} and Peter Schmidt and Anita Pakrasi and Lucy Artinian and Murray, {Natalie G B} and Imagawa, {David K.} and Curtis Holt and Goldstein, {Leonard I.} and Ris{\"e} Stribling and Busuttil, {Ronald W.}",
year = "1998",
month = "8",
day = "17",
doi = "10.1002/hep.510280241",
language = "English",
volume = "28",
pages = "585--589",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

AU - Markowitz, Jay S.

AU - Martin, Paul

AU - Conrad, Andrew J.

AU - Markmann, James F.

AU - Seu, Philip

AU - Yersiz, Hasan

AU - Goss, John A.

AU - Schmidt, Peter

AU - Pakrasi, Anita

AU - Artinian, Lucy

AU - Murray, Natalie G B

AU - Imagawa, David K.

AU - Holt, Curtis

AU - Goldstein, Leonard I.

AU - Stribling, Risë

AU - Busuttil, Ronald W.

PY - 1998/8/17

Y1 - 1998/8/17

N2 - Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA and improving histology in patients with hepatitis B infection; its role in prophylaxis against hepatitis B recurrence following liver transplantation is under investigation. Viral breakthrough and resistance, however, are a significant problem with monotherapy with either HBIG or lamivudine. The efficacy of combination lamivudine/JHBIG prophylaxis has not been reported. Fourteen patients underwent transplantation for decompensated liver disease owing to hepatitis B. Lamivudine (50 mg po/d) was begun before transplantation in 0 patients, including 4 who were HBV DNA-positive. In addition, 1 patient was HBV DNA-positive when transplanted. HBIG was given perioperatively and continued thereafter; treatment with lamivudine was maintained or initiated at the time of transplantation and continued indefinitely. The median follow-up was 387 days. Actuarial 1-year patient and graft survival was 93% (patient died of unrelated causes). At a median interval of 28 days following lamivudine treatment, all 5 HBV DNA-positive patients cleared HBV DNA from the serum; went on to clear hepatitis B surface antigen (HBsAg), before transplantation, at day 148 of lamivudine treatment. By the highly sensitive polymerase chain reaction (PCR), at a median of 346 days (range, 130-525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA. Lamivudine suppresses HBV replication in patients awaiting liver transplantation. At a median follow- up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.

AB - Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA and improving histology in patients with hepatitis B infection; its role in prophylaxis against hepatitis B recurrence following liver transplantation is under investigation. Viral breakthrough and resistance, however, are a significant problem with monotherapy with either HBIG or lamivudine. The efficacy of combination lamivudine/JHBIG prophylaxis has not been reported. Fourteen patients underwent transplantation for decompensated liver disease owing to hepatitis B. Lamivudine (50 mg po/d) was begun before transplantation in 0 patients, including 4 who were HBV DNA-positive. In addition, 1 patient was HBV DNA-positive when transplanted. HBIG was given perioperatively and continued thereafter; treatment with lamivudine was maintained or initiated at the time of transplantation and continued indefinitely. The median follow-up was 387 days. Actuarial 1-year patient and graft survival was 93% (patient died of unrelated causes). At a median interval of 28 days following lamivudine treatment, all 5 HBV DNA-positive patients cleared HBV DNA from the serum; went on to clear hepatitis B surface antigen (HBsAg), before transplantation, at day 148 of lamivudine treatment. By the highly sensitive polymerase chain reaction (PCR), at a median of 346 days (range, 130-525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA. Lamivudine suppresses HBV replication in patients awaiting liver transplantation. At a median follow- up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=17344364991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344364991&partnerID=8YFLogxK

U2 - 10.1002/hep.510280241

DO - 10.1002/hep.510280241

M3 - Article

VL - 28

SP - 585

EP - 589

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -